Inflammation and cancer risk: an evaluation of biomarker profiles
Several recent reports have provided data that cancer development is substantially controlled by the immune system, and that immunotherapy may be a credible strategy in cancer. Chronic inflammatory conditions such as reflux esophagitis (oesophageal cancer), inflammatory bowel disease and chronic ulcerative colitis (colorectal cancer), chronic pancreatitis (pancreatic cancer), asbestosis (lung cancer), as well as infections like hepatitis (hepatocellular cancer) and mononucleosis (Burkett’s Lymphoma) have been linked to carcinogenesis. However, the use of inflammatory biomarkers as early predictive markers has been disappointing. For instance, studies evaluating the associations of C-reactive protein, a commonly used inflammation-related biomarker, with colorectal cancer (CRC) risk have yielded conflicting results despite CRC being an archetypal inflammation-related cancer.
We encourage investigators to contribute original research articles, reviews, or opinions that will stimulate the continuing efforts to understand the suggested pathways between the immune system and cancer development. With a better understanding of the association between the immune system and risk of cancer, it might be possible to identify targets that can slow down or even prevent the development of cancer. We are particularly interested in articles that explore the association between the immune system and cancer in innovative ways in humans and also in animal models.
Potential topics include, but are not limited to:
• The refinement of widely used biomarkers in evaluating cancer risk and survival
• The use of more sensitive inflammation-related biomarkers
• The exploration of new methodological designs to evaluate the associations of inflammatory biomarkers with cancer
• The use of inflammatory biomarkers in guiding treatment decisions for cancer patients
European Journal of Clinical Oncology
Mail ID: email@example.com
WhatsApp no: + 1-504-608-2390